0001144204-18-014636.txt : 20180314
0001144204-18-014636.hdr.sgml : 20180314
20180314160114
ACCESSION NUMBER: 0001144204-18-014636
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180312
FILED AS OF DATE: 20180314
DATE AS OF CHANGE: 20180314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CARUSO JAMES V
CENTRAL INDEX KEY: 0001202770
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36598
FILM NUMBER: 18689458
MAIL ADDRESS:
STREET 1: C/O CELLECTAR BIOSCIENCES, INC.
STREET 2: 3301 AGRICULTURE DRIVE
CITY: MADISON
STATE: WI
ZIP: 53716
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cellectar Biosciences, Inc.
CENTRAL INDEX KEY: 0001279704
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043321804
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3301 AGRICULTURE DRIVE
CITY: MADISON
STATE: WI
ZIP: 53716
BUSINESS PHONE: (608) 441-8120
MAIL ADDRESS:
STREET 1: 3301 AGRICULTURE DRIVE
CITY: MADISON
STATE: WI
ZIP: 53716
FORMER COMPANY:
FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20050617
FORMER COMPANY:
FORMER CONFORMED NAME: COMMON HORIZONS INC
DATE OF NAME CHANGE: 20040211
4
1
tv488453_4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-03-12
0
0001279704
Cellectar Biosciences, Inc.
CLRB
0001202770
CARUSO JAMES V
C/O CELLECTAR BIOSCIENCES, INC.
3301 AGRICULTURE DRIVE
MADISON
WI
53716
1
1
0
0
President and CEO
Common Stock
2018-03-12
4
S
0
34000
1.1972
D
213548
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2017 to satisfy tax withholding obligations upon vesting of restricted stock.
The price reported in Column 4 of Line 1 with respect to the 34,000 shares sold on March 12, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.26. The Reporting Person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (2) to this Form 4.
/s/ Christina Blakley, attorney-in-fact for James Caruso
2018-03-14